GetTopicDetailResponse(id=1ba85880eda, topicName=施維雅, introduction=施維雅, content=null, image=null, comments=5, allHits=2042, url=https://h5.medsci.cn/topic?id=58807, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=18249, tagList=[TagDto(tagId=18249, tagName=施維雅)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2220366, encodeId=620522203660a, content=<a href='/topic/show?id=41651083831e' target=_blank style='color:#2F92EE;'>#Vorasidenib#</a>是由<a href='/topic/show?id=1ba85880eda' target=_blank style='color:#2F92EE;'>#施維雅#</a>公司開發(fā)的<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>和IDH2突變酶的雙重抑制劑，可通過口服給藥，能夠穿越血腦屏障，到達(dá)<a href='/topic/show?id=53668406668' target=_blank style='color:#2F92EE;'>#膠質(zhì)瘤#</a>部位，大幅提高患者的生存!!
<a href='/topic/show?id=b35011e938cd' target=_blank style='color:#2F92EE;'>#沃拉西尼#</a>
, objectTitle=NEJM：20多年來膠質(zhì)瘤治療的首個(gè)重大突破，大幅延長(zhǎng)患者生存期, objectType=article, longId=775467, objectId=fe17e7546715, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230606/1686014563030_5295905.jpg, objectUrl=/article/show_article.do?id=fe17e7546715, replyNumber=0, likeNumber=123, createdTime=2024-08-15, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=fe17e7546715, moduleTitle=NEJM：20多年來膠質(zhì)瘤治療的首個(gè)重大突破，大幅延長(zhǎng)患者生存期, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fe17e7546715)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1495678, encodeId=b8cc14956e8f1, content=<a href='/topic/show?id=1ba85880eda' target=_blank style='color:#2F92EE;'>#施維雅#</a>, objectTitle=法國(guó)第二大制藥公司施維雅（Servier）24億美元收購(gòu)Shire公司的腫瘤業(yè)務(wù)經(jīng)營(yíng)權(quán), objectType=article, longId=147989, objectId=442014e9890d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442014e9890d, replyNumber=0, likeNumber=104, createdTime=2018-09-02, rootId=0, userName=chentianping, userId=b34a9182631, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442014e9890d, moduleTitle=法國(guó)第二大制藥公司施維雅（Servier）24億美元收購(gòu)Shire公司的腫瘤業(yè)務(wù)經(jīng)營(yíng)權(quán), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=442014e9890d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1495677, encodeId=b04814956e717, content=<a href='/topic/show?id=1ba85880eda' target=_blank style='color:#2F92EE;'>#施維雅#</a>, objectTitle=美國(guó)FDA批準(zhǔn)施維雅/輝瑞通用型CAR-T療法進(jìn)入臨床試驗(yàn), objectType=article, longId=92101, objectId=8c7e921016c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c7e921016c, replyNumber=0, likeNumber=106, createdTime=2017-03-15, rootId=0, userName=chentianping, userId=b34a9182631, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c7e921016c, moduleTitle=美國(guó)FDA批準(zhǔn)施維雅/輝瑞通用型CAR-T療法進(jìn)入臨床試驗(yàn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8c7e921016c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1495676, encodeId=725414956e667, content=<a href='/topic/show?id=1ba85880eda' target=_blank style='color:#2F92EE;'>#施維雅#</a>, objectTitle=大冢及施維雅結(jié)直腸癌復(fù)方新藥Lonsurf英國(guó)NICE批準(zhǔn), objectType=article, longId=75978, objectId=2011e597805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2011e597805, replyNumber=0, likeNumber=142, createdTime=2016-08-28, rootId=0, userName=chentianping, userId=b34a9182631, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2011e597805, moduleTitle=大冢及施維雅結(jié)直腸癌復(fù)方新藥Lonsurf英國(guó)NICE批準(zhǔn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2011e597805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1495675, encodeId=485214956e5d1, content=<a href='/topic/show?id=1ba85880eda' target=_blank style='color:#2F92EE;'>#施維雅#</a>, objectTitle=施維雅腎臟病青年研究與發(fā)展項(xiàng)目2014年項(xiàng)目申報(bào)通知, objectType=article, longId=33751, objectId=e64d33e51cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e64d33e51cc, replyNumber=0, likeNumber=102, createdTime=2014-04-25, rootId=0, userName=chentianping, userId=b34a9182631, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e64d33e51cc, moduleTitle=施維雅腎臟病青年研究與發(fā)展項(xiàng)目2014年項(xiàng)目申報(bào)通知, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e64d33e51cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
